CMXHF
Price:
$171.54
Market Cap:
$83.06B
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufact...[Read more]
Industry
Biotechnology
IPO Date
2005-11-18
Stock Exchange
PNK
Ticker
CMXHF
According to CSL Limited’s latest financial reports and current stock price. The company's current PE Ratio is 31.48. This represents a change of -18.88% compared to the average of 38.81 of the last 4 quarters.
The mean historical PE Ratio of CSL Limited over the last ten years is 45.10. The current 31.48 PE Ratio has changed 6.88% with respect to the historical average. Over the past ten years (40 quarters), CMXHF's PE Ratio was at its highest in in the March 2023 quarter at 82.15. The PE Ratio was at its lowest in in the December 2023 quarter at 11.87.
Average
45.10
Median
44.61
Minimum
28.97
Maximum
61.75
Discovering the peaks and valleys of CSL Limited PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 41.33%
Maximum Annual PE Ratio = 61.75
Minimum Annual Increase = -31.36%
Minimum Annual PE Ratio = 28.97
Year | PE Ratio | Change |
---|---|---|
2024 | 35.10 | -14.73% |
2023 | 41.16 | 7.60% |
2022 | 38.25 | -31.36% |
2021 | 55.73 | -9.74% |
2020 | 61.75 | 21.04% |
2019 | 51.01 | 2.00% |
2018 | 50.01 | 4.08% |
2017 | 48.05 | 17.36% |
2016 | 40.94 | 41.33% |
2015 | 28.97 | 17.81% |
The current PE Ratio of CSL Limited (CMXHF) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
38.17
5-year avg
46.40
10-year avg
45.10
CSL Limited’s PE Ratio is greater than PMV Pharmaceuticals, Inc. (-1.61), less than Novo Nordisk A/S (35.33), greater than KalVista Pharmaceuticals, Inc. (-3.31), greater than ProKidney Corp. (-4.19), greater than Ventyx Biosciences, Inc. (-0.86), greater than Bionomics Limited (-0.22), greater than CSL Limited (18.43), greater than Enzon Pharmaceuticals, Inc. (3.90), greater than Legend Biotech Corporation (-21.42), greater than Zai Lab Limited (-9.58), greater than Seagen Inc. (-100.71), greater than Alnylam Pharmaceuticals, Inc. (-94.78), greater than Ascendis Pharma A/S (-16.63), greater than Beam Therapeutics Inc. (-14.38), greater than Intellia Therapeutics, Inc. (-2.77), greater than Editas Medicine, Inc. (-0.96), greater than Verve Therapeutics, Inc. (-2.07), greater than Prime Medicine, Inc. (-1.75),
Company | PE Ratio | Market cap |
---|---|---|
-1.61 | $83.31M | |
35.33 | $465.61B | |
-3.31 | $494.46M | |
-4.19 | $492.99M | |
-0.86 | $130.81M | |
-0.22 | $8.81M | |
18.43 | $87.16B | |
3.90 | $5.94M | |
-21.42 | $7.51B | |
-9.58 | $2.75B | |
-100.71 | $43.15B | |
-94.78 | $31.59B | |
-16.63 | $7.76B | |
-14.38 | $2.07B | |
-2.77 | $1.46B | |
-0.96 | $201.42M | |
-2.07 | $410.62M | |
-1.75 | $419.71M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like CSL Limited using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like CSL Limited or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is CSL Limited's PE Ratio?
How is the PE Ratio calculated for CSL Limited (CMXHF)?
What is the highest PE Ratio for CSL Limited (CMXHF)?
What is the 3-year average PE Ratio for CSL Limited (CMXHF)?
What is the 5-year average PE Ratio for CSL Limited (CMXHF)?
How does the current PE Ratio for CSL Limited (CMXHF) compare to its historical average?